Extracell Vesicles Circ Nucleic Acids. EVCNA Extracellular Vesicles and Circulating Nucleic Acids 2767-6641 OAE Publishing Inc. 10.20517/evcna.2026.14 Review Stem cell extracellular vesicles for neuropsychiatric disorders and translation Fan Hengxiang 1 # Wang Shunqi 1 # Li Zhi 2 Yu Tianze 2 Ma Chaolin 1 Sun Chong 1 1Department of Neurology, The Second Affiliated Hospital, Institute of Biomedical Innovation, Jiangxi Province Key Laboratory of Brain Science and Brain Health, and School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang 330031, Jiangxi, China. 2Queen Mary School, Jiangxi Medical College, Nanchang University, Nanchang 330031, Jiangxi, China. #These authors contributed equally to this work. Correspondence to: Prof. Chaolin Ma, Dr. Chong Sun, Department of Neurology, The Second Affiliated Hospital, Institute of Biomedical Innovation, Jiangxi Province Key Laboratory of Brain Science and Brain Health, and School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang 330031, Jiangxi, China. E-mail: chaolinma@ncu.edu.cn; sunc@ncu.edu.cn

Received: 31 Jan 2026 | First Decision: 19 Mar 2026 | Revised: 7 Apr 2026 | Accepted: 18 May 2026 | Published: 29 May 2026

Academic Editors: Yoke Peng Loh, Shilpa Buch | Copy Editor: Ting-Ting Hu | Production Editor: Ting-Ting Hu

 2026 29 5 2026 7 2 764 85 © The Author(s) 2026. © The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Neuropsychiatric disorders represent a major global health challenge due to their high prevalence, chronic disability, and substantial socioeconomic burden. Although stem cell-based therapies offer regenerative potential, their clinical application is limited by poor post-transplantation survival, restricted targeted integration, and potential tumorigenicity. Stem cell-derived extracellular vesicles (SC-EVs), particularly exosomes, have emerged as a promising cell-free therapeutic approach. These vesicles can cross the blood-brain barrier (BBB) and exhibit high biocompatibility and low immunogenicity. This review summarizes the cellular origins and biogenesis of SC-EVs and evaluates current preclinical and clinical evidence supporting their therapeutic potential. Particular attention is given to acute ischemic stroke and progressive neurodegenerative disorders, including Alzheimer’s disease and Parkinson’s disease. In addition, the molecular mechanisms underlying their neuroprotective and regenerative effects are discussed, with a focus on modulating neuroinflammation, promoting neurogenesis, and enhancing synaptic plasticity. Finally, key advances and major challenges in the clinical translation of SC-EVs are outlined. Integrating current evidence, this review provides a framework and practical perspective for the continued development of SC-EV-based therapies for complex neurological disorders.

 Stem cell-derived extracellular vesicles neuropsychiatric disorders neuroinflammation neuroregeneration INTRODUCTION

Neurological disorders are a major global public health challenge, affecting approximately 3.4 billion people and causing nearly 11.8 million deaths annually, thereby imposing a heavy socioeconomic burden[1]. As the global population ages, the incidence of these disorders continues to rise, placing increasing pressure on healthcare systems[2]. A major obstacle to effective neurotherapeutics is the blood-brain barrier (BBB), which prevents most small molecules and nearly all macromolecular biologics from entering the central nervous system (CNS)[3]. In addition, neuronal damage in these disorders is complex, heterogeneous, and often irreversible, which limits the effectiveness of conventional monotherapies[4]. These challenges highlight the need for novel, multifaceted regenerative strategies.

Stem cells, characterized by self-renewal, proliferation, and multilineage differentiation, are considered promising candidates for the treatment of neurological disorders[5,6]. Common types include mesenchymal stem cells (MSCs), neural stem cells (NSCs), induced pluripotent stem cells (iPSCs), and embryonic stem cells (ESCs). These cells exert therapeutic effects through multiple mechanisms, including cell replacement, immunomodulation[7], anti-inflammatory effects, promotion of angiogenesis, and enhancement of neuroprotection[8]. However, increasing evidence indicates that their therapeutic benefits are largely mediated by paracrine signaling rather than direct in vivo engraftment[9].

Despite their therapeutic potential, current stem cell-based therapies face translational challenges. Intrinsic cellular heterogeneity complicates controlled differentiation and the standardization of clinical outcomes[10]. Moreover, poor post-transplantation survival and poor homing to injury sites limit efficacy, and there is a risk of immune rejection in allogeneic settings[11]. In addition, undifferentiated stem cells may form tumors, so careful safety measures such as rigorous purification and phenotypic validation are required before clinical use[12].

In this context, stem cell-derived extracellular vesicles (SC-EVs) have emerged as a promising cell-free alternative. SC-EVs retain key regenerative and immunomodulatory components of their parent cells while avoiding many of the safety, immunological, and engraftment limitations associated with live-cell transplantation[5,6]. Although previous studies have summarized general aspects of extracellular vesicle biology, this review provides a focused and clinically oriented overview of SC-EV-mediated neurological repair, organized into six principal mechanistic categories: immunomodulation, mitochondrial homeostasis, neuroprotection, enhancement of neuroplasticity, angiogenesis, and clearance of pathological protein aggregates.

This review focuses primarily on conditions supported by strong preclinical and translational evidence, including acute ischemic injury (stroke) and progressive neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease (PD). Emerging applications in neuropsychiatric disorders (e.g., epilepsy, schizophrenia, and major depressive disorder) are also discussed. These conditions are increasingly recognized not only as disorders of neurotransmission but also as involving structural and neuroinflammatory alterations in the CNS, making them relevant targets for SC-EV-based interventions. Finally, to bridge the gap between experimental research and clinical application, we evaluate the current clinical trial landscape and highlight key methodological challenges, including EV heterogeneity, isolation-related biases, and the lack of standardized characterization criteria that must be addressed to enable reliable clinical translation.

 LITERATURE SEARCH STRATEGY

A comprehensive literature search [Figure 1] was conducted to identify relevant studies on SC-EVs in neurological disorders. The major electronic databases, including PubMed, Web of Science, and Scopus, were systematically searched for articles published from 2015 to 2025. The search strategy combined keyword and Medical Subject Headings (MeSH) terms related to “stem cell-derived extracellular vesicles,” “isolation and purification,” and specific neurological disorders (e.g., stroke, epilepsy, schizophrenia, depression, neuropsychiatric diseases, neurodegenerative diseases).

PRISMA flow diagram. This study followed the PRISMA 2020 guidelines for systematic literature screening. The initial search of databases and clinical trial registries yielded 759 records (749 from databases and websites and 10 from registries). After removing 372 duplicate records and 12 records excluded for other reasons, 375 records remained for screening. Title and abstract screening excluded 212 records that did not meet the inclusion criteria. Of the 163 records selected for full-text review, 5 could not be retrieved, leaving 158 articles for eligibility assessment. At this stage, 8 articles were excluded due to inconsistent study design, inappropriate study populations, or missing essential data. Ultimately, 150 records (148 journal articles and 2 registry entries) were included in final evidence synthesis. PRISMA: Preferred Reporting Items for Systematic reviews and Meta-Analyses.

Eligible studies included original research articles, preclinical studies, and clinical investigations that evaluated the therapeutic potential or underlying mechanisms of SC-EVs in neurological contexts. Review articles were also screened to identify additional relevant references. Studies not published in English or lacking sufficient methodological detail were excluded.

Two independent reviewers screened titles and abstracts for relevance, followed by full-text assessment of eligible articles. Discrepancies were resolved through discussion and consensus. Data extraction focused on study design, source of stem cells, EV isolation methods, experimental models, therapeutic outcomes, and mechanistic findings.

 SC-EVS: BIOGENESIS, SECRETION AND CELLULAR SOURCE Overview of SC-EVs

SC-EVs are nanoscale, membrane-bound vesicles (typically 30-150 nm in diameter) released by cells and involved in intercellular communication[13]. Their biological activity is mediated by cargo that includes proteins, lipids, and nucleic acids[14]. Proteomic analyses have identified enrichment of specific surface receptors, cytoskeletal components, and signaling molecules within these vesicles[15].

According to the Minimal Information for Studies of Extracellular Vesicles (MISEV) guidelines[16,17], the characterization of SC-EVs requires a multiparametric approach. Morphology and size distribution should be assessed using complementary high-resolution techniques, such as transmission electron microscopy (for morphology) and nanoparticle tracking analysis or tunable resistive pulse sensing (for size distribution and concentration). Quantification should include both total particle number and total protein content, as the particle-to-protein ratio provides an indirect measure of sample purity.

To confirm vesicle identity, protein profiling should demonstrate the presence of at least one transmembrane or lipid-associated marker (e.g., CD9, CD63, CD81) together with a cytosolic EV-associated protein [e.g., tumor susceptibility gene 101 (TSG101) or ALG-2-interacting protein X (Alix)]. In addition, at least one negative marker (e.g., calnexin for the endoplasmic reticulum or GM130 for the Golgi apparatus) should be evaluated to exclude contamination from intracellular organelles. Screening for common non-vesicular contaminants, including lipoproteins and protein aggregates, is also necessary to ensure that observed functional effects are attributable to EVs. Because no single method can fully define EV identity or purity, the combined use of multiple approaches is recommended[17].

In addition to proteins, SC-EVs contain nucleic acids, including messenger ribonucleic acid (mRNA), micro ribonucleic acid (miRNA), and DNA fragments. Among these components, miRNAs are particularly important because they regulate gene expression and mediate intercellular communication. The miRNA composition of SC-EVs varies according to the cellular source, resulting in distinct regulatory profiles[17,18]. The lipid composition of SC-EVs also contributes to their biological activity. Enrichment of cholesterol, sphingolipids, and phosphatidylserine supports membrane stability and facilitates processes such as membrane fusion and endocytosis. Lipidomic studies further indicate that source-specific lipid profiles influence cargo loading and target cell interactions[19-22].

 Biogenesis and release of SC-EVs

SC-EVs are formed through the maturation of multivesicular bodies (MVBs). During this process, the endosomal membrane invaginates to encapsulate selected cytosolic components, forming intraluminal vesicles (ILVs). These MVBs subsequently fuse with the plasma membrane, releasing ILVs into the extracellular space as vesicles enriched in tetraspanins such as CD63[23].

The sorting and budding of vesicles are primarily regulated by the endosomal sorting complex required for transport (ESCRT) machinery. This system consists of four sub-complexes (ESCRT-0, -I, -II, and -III), which function sequentially to recognize ubiquitinated cargo, induce membrane invagination, and mediate vesicle scission. Accessory proteins such as hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) and TSG101 facilitate cargo clustering, while VPS4 mediates membrane scission and complex disassembly[24].

In addition to ESCRT-dependent pathways, SC-EVs can also be generated through ESCRT-independent mechanisms. One major pathway involves ceramide generation by neutral sphingomyelinases, which induces membrane curvature and promotes ILV formation. This process can be inhibited by neutral sphingomyelinase inhibitors such as GW4869. Tetraspanins (such as CD9, CD63, CD81) also contribute to cargo organization through membrane microdomains, independent of ubiquitination. Other proteins, including SIMPLE and Ndfip1, participate in cargo recruitment[23]. The coexistence of multiple biogenesis pathways within a single cell contributes to the heterogeneity of EV subpopulations [Figure 2].

Biogenesis and Release of SC-EVs. This schematic illustrates the cellular pathways involved in the formation, maturation, and secretion of SC-EVs. The upper panel represents the parent stem cell, whereas the lower panel depicts key stages of vesicle biogenesis. The process begins with invagination of the plasma membrane to form early endosomes, which subsequently mature into late endosomes or MVBs. During this process, inward budding of the endosomal membrane encapsulates selected proteins, lipids, and nucleic acids within ILVs. Cargo sorting is regulated by both ESCRT-dependent and ESCRT-independent mechanisms. Upon maturation, MVBs fuse with the plasma membrane, releasing ILVs into the extracellular space as exosomes. In contrast, microvesicles are generated through direct outward budding and fission of the plasma membrane. SC-EVs: Stem cell-derived extracellular vesicles; ESCRT: endosomal sorting complex required for transport; HRS: hepatocyte growth factor-regulated tyrosine kinase substrate; TSG101: tumor susceptibility gene 101; VPS4: vacuolar protein sorting-associated protein 4; ILV: intraluminal vesicle; MVB: multivesicular body; SIMPLE：small integral membrane protein of the endosome; Ndfip1: Nedd4 family interacting protein 1; DNA: deoxyribonucleic acid; RNA: ribonucleic acid.

 Cellular sources of SC-EVs MSCs

MSCs are among the most extensively studied sources of therapeutic extracellular vesicles. Although MSC-derived EVs express canonical tetraspanins (CD9, CD63, and CD81), their secretomes exhibit substantial heterogeneity[25-29], which affects their functional properties, as does methodological variation during isolation[30-32].

Among MSC subtypes, bone marrow-derived MSCs (BMSCs) show strong neuroprotective potential but are limited by invasive harvesting procedures and batch variability[15,33-37]. In contrast, umbilical cord-derived MSCs (UCMSCs) provide a scalable and low-immunogenic alternative that is suitable for clinical applications[36,38-42]. Adipose-derived MSCs (ADMSCs) offer high yield through minimally invasive collection[43-46]; however, their isolation requires careful enzymatic processing to avoid altering EV composition[15,47,48].

 Pluripotent stem cells

Embryonic stem cell-derived EVs (ESC-EVs) contain potent regenerative cargo; however, their clinical use is limited by ethical concerns and the risk of teratoma formation[49-55]. iPSCs provide a more practical alternative for personalized therapy[37,56]. iPSC-derived EVs are enriched in developmental miRNAs and regulatory factors that promote angiogenesis and tissue repair. However, because their secretome can be highly dynamic, careful isolation and characterization are required to ensure consistency and reproducibility.

 Neural stem and progenitor cells

Neural stem/progenitor cells (NSCs/NPCs) produce EVs that are suited for CNS repair[57]. These vesicles are enriched in neural-specific miRNAs and synapse-associated proteins[58-60], supporting neuroprotection, anti-inflammatory effects, and axonal regeneration[61,62]. Large-scale production of NSC-derived EVs often relies on high-throughput methods such as Tangential flow filtration (TFF) for EV concentration; careful validation is required to preserve EV integrity and function.

 Isolation of SC-EVs

The isolation of SC-EVs from conditioned media remains a key technical challenge. Consistent with MISEV guidelines, no single method can be considered universally optimal; instead, each approach introduces specific biases that influence the composition of recovered EV populations[63-65]. Differential ultracentrifugation is widely used but may cause vesicle aggregation and co-isolation of contaminants such as protein complexes and lipoproteins. Size-exclusion chromatography (SEC) improves purity and preserves vesicle integrity; however, it often results in sample dilution and may require additional concentration steps[64-66]. Density gradient centrifugation, particularly with iodixanol, enables high-resolution separation based on buoyant density and reduces contamination from other similarly sized particles[64,67].

Immunoaffinity capture using antibodies against surface markers (e.g., CD9 or CD63) allows selective enrichment of EV subpopulations but is limited by low throughput and potential interference with surface proteins[64,68]. Overall, the choice of isolation method influences EV composition and functional outcomes, thus highlighting the need for standardized characterization [Table 1].

Methodological overview for stem cell-derived extracellular vesicle isolation

Method/Technique Principle Key advantages Major limitations
Differential ultracentrifugation Sequential centrifugation based on size/density sedimentation Widely applicable[69,70] Time-consuming; requires specialized equipment; Non-specific co-precipitation; vesicle damage/aggregation[71-73]
Size-exclusion chromatography Separation by hydrodynamic volume using a porous column matrix High purity; preserves vesicle integrity and function[74,75] Moderate throughput; sample dilution[17,76,77]
Ultrafiltration Size-based separation using membranes with defined molecular weight cut-offs Scalable; suitable for processing large volumes[78] Risk of vesicle deformation or membrane clogging[79]
Density gradient centrifugation Separation based on buoyant density within a gradient medium High-resolution separation from contaminants of similar sizes[64,67,80] Labor-intensive; requires long centrifugation times[81]
Immunoaffinity capture Selective binding using antibodies targeting specific surface markers High specificity for distinct subpopulations or sources[82] High cost; potential for antibody contamination; low throughput[64,68,79]
PRECLINICAL RESEARCH OF EVS IN NEUROLOGICAL DISORDERS Immunomodulation and anti-neuroinflammation

The modulation of neuroinflammation is a core mechanism underlying the therapeutic effects of SC-EVs across neurological disorders. These effects involve regulation of glial activation states, suppression of pro-inflammatory mediators, and promotion of immune phenotypes associated with tissue repair.

Stroke: modulation of microglial dynamics and inflammatory cascades

In ischemic stroke, SC-EVs deliver molecular cargo that modulates inflammatory cascades and mitigates ischemia-reperfusion (I/R) injury. A key mechanism involves promoting a shift in microglia from a pro-inflammatory (M1-like) state toward a neuroprotective (M2-like) phenotype. For example, BMSC-EVs enriched in the lncRNA zinc finger antisense 1 (ZFAS1) reduce microglial activation by downregulating miR-15a-5p[83], while other EV populations suppress the NLR family pyrin domain containing 3 (NLRP3) inflammasome to attenuate neuronal pyroptosis[84]. SC-EVs also influence post-transcriptional and post-translational regulation. BMSC-EVs carrying the lncRNA Krüppel-like factor 3 antisense RNA 1 (KLF3-AS1) inhibit sirtuin 1 (Sirt1) ubiquitination via USP22, alleviating I/R-induced injury[85]. In addition, UCMSC-EVs modulate microglial activity through high-mobility group box 1 (HMGB1)-mediated activation of the triggering receptor expressed on myeloid cells 1 (TREM1)-p38 mitogen-activated protein kinase (MAPK) pathway, whereas NSC-EVs deliver miR-125a-5p to inhibit the toll-like receptor 4 (TLR4)/nuclear factor-kappa B (NF-κB) signaling axis[86-88]. SC-EVs also reduce oxidative stress, for example by targeting the fat mass and obesity-associated protein (FTO)/N6-methyladenosine (m6A)/ dynamin-related protein (Drp1) pathway, which indirectly attenuates inflammation-associated neuronal injury[89].

 Neurodegenerative diseases: restoration of immune homeostasis and microglial balance

In Alzheimer’s disease (AD), SC-EVs reduce amyloid-β (Aβ) accumulation and associated glial activation, leading to decreased expression of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6)[90]. In parallel, they increase brain-derived neurotrophic factor (BDNF) expression[91] and promote a shift in microglial phenotype toward a reparative state. These changes may partially counteract age-associated inflammatory processes[92,93] and reduce reactive astrogliosis[94].

In PD, SC-EVs suppress inflammatory signaling in the substantia nigra, which is important for protecting dopaminergic neurons. Engineered BMSC-EVs (e.g., AK76 or quercetin-loaded EVs) promote M2-like polarization[95], while Gli1-containing EVs inhibit Sp1-mediated activation of Leucine-rich repeat kinase 2 (LRRK2)[96]. UCMSC-EVs are preferentially internalized by activated microglia in lesion areas, contributing to localized immunomodulation and preservation of neuronal integrity[97,98].

 Emerging applications in neuropsychiatric disorders

In epilepsy, SC-EVs affect the interaction between neuroinflammation and neuronal hyperexcitability. ADMSC-EVs deliver miR-23b-3p to regulate the signal transducer and activator of transcription 1 (STAT1)/Glyoxylate reductase 1 homolog (GLYR1) axis and promote microglial phenotype transition[99,100], while UCMSC-EVs activate nuclear factor erythroid 2-related factor 2 (NRF2) signaling to inhibit NLRP3 inflammasome activation[101,102]. iPSC-EVs also suppress inflammatory signaling via the lncRNA-0949-TLR4/MAPK/NF-κB pathway[103].

In psychiatric disorder models, SC-EVs modulate inflammatory balance. In schizophrenia, MSC-EVs reduce pro-inflammatory cytokine expression while increasing IL-10 levels[104]. In depression models, UCMSC-EVs inhibit the myeloid differentiation primary response 88 (MyD88)/tumor necrosis factor receptor-associated factor 6 (TRAF6)/NF-κB pathway via miR-125b-5p, thereby reducing neuroinflammation and synaptic impairment[105]. ADMSC-EVs also activate adenosine monophosphate-activated protein kinase (AMPK)-dependent autophagy and suppress NLRP3 signaling[106].

 Critical appraisal and translational gaps

Although SC-EVs consistently attenuate neuroinflammation in preclinical studies, several limitations affect translational interpretation. First, many studies rely on the simplified M1/M2 polarization framework, whereas microglial activation in vivo represents a continuous and heterogeneous spectrum, including disease-associated microglia (DAM). Second, experimental models often focus on microglia in isolation, with limited consideration of interactions with astrocytes, endothelial cells, and peripheral immune components. Finally, variability in cytokine measurement and experimental design reduces cross-study comparability and reproducibility.

 Regulation of oxidative stress and mitochondrial homeostasis

Oxidative stress and mitochondrial dysfunction are common features of ischemic, neurodegenerative, and psychiatric disorders. SC-EVs reduce lipid peroxidation and support mitochondrial function through delivery of regulatory RNAs and proteins.

Stroke and PD: targeted modulation of redox status and mitophagy

In ischemic stroke, SC-EVs stabilize mitochondrial dynamics. For example, BMSC-EVs regulate the Krüppel-like factor 4 (KLF4)-FTO pathway and reduce the m6A modification of Drp1, thereby limiting mitochondrial fragmentation[89]. SC-EVs also reduce reactive oxygen species (ROS) production through mechanisms involving the lncRNA ZFAS1[83] and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling[88]. In addition, NSC-EVs activate PINK1/Parkin-mediated mitophagy, promoting removal of damaged mitochondria[107].

Similar mechanisms are observed in PD models. SC-EVs reduce oxidative stress in the substantia nigra and protect dopaminergic neurons. Both NSC-EVs[98] and engineered BMSC-EVs[95] decrease ROS levels and reduce neuronal loss in toxin-induced models.

 Depression: antioxidant signaling and neuroprotection

Depression is increasingly associated with chronic oxidative stress and metabolic dysfunction alongside classical neurotransmitter imbalance. In this context, the therapeutic effects of SC-EVs are partly mediated by regulating redox homeostasis. BMSC-EVs increase hippocampal miR-26a levels and reduce oxidative damage markers, including malondialdehyde and nitric oxide[108]. In parallel, SC-EVs modulate downstream signaling pathways such as MAPK and NF-κB, thereby reducing apoptosis and supporting synaptic function[109]. These findings suggest that regulation of mitochondrial function and oxidative stress contributes to the neuroprotective effects of SC-EVs in depression models.

 Critical appraisal and translational gaps

Despite consistent antioxidant effects in preclinical studies, several limitations remain. Most experimental models rely on acute oxidative stress paradigms that fail to reflect the chronic and progressive nature of mitochondrial dysfunction in human disease. In addition, the transient nature of ROS, together with variability in detection methods, complicates cross-study comparisons. The limited availability of in vivo tracking approaches makes it difficult to determine whether administered SC-EVs effectively reach target cells and interact with mitochondrial pathways.

 Neuronal protection and anti-apoptotic signaling

Programmed cell death is a common feature of both acute brain injury and chronic neurodegeneration. SC-EVs exert neuroprotective effects by modulating apoptotic pathways, reducing excitotoxicity, and preserving neuronal structure and function.

Stroke and AD: suppression of cell death pathways

In ischemic stroke, SC-EVs influence multiple forms of cell death. ADMSC-EVs deliver miR-25-3p to hypoxic neurons, suppressing p53 and the B-cell lymphoma 2 (BCL2)-interacting protein 3, thereby restoring autophagic balance and reducing apoptosis[110]. They also inhibit ferroptosis by targeting CHAC1 via miR-760-3p[111]. In addition, UCMSC-EVs regulate PI3K/AKT and MAPK signaling, decreasing pro-apoptotic factors (Bax, Caspase-3) while increasing anti-apoptotic Bcl-2 expression[112].

In AD models, SC-EVs reduce amyloid-associated neurotoxicity and support neuronal survival. BMSC-EVs increase expression of neuronal and neurogenic markers [neuronal nuclei (NeuN), NeuroD1, BDNF][91,113,114], while UCMSC-EVs reduce Aβ burden and partially restore synaptic gene expression[115]. NSC-EVs also activate Sirt1 signaling to support mitochondrial function under amyloid stress[94].

 PD, epilepsy, and schizophrenia: targeted neuroprotection

In PD models, SC-EVs protect dopaminergic neurons through metabolic and autophagy-related mechanisms. Engineered BMSC-EVs (AK76 and quercetin) promote autophagy[95], while EV-associated tumor necrosis factor stimulated gene 6 protein (TSG 6) reduces 1-methyl-4-phenylpyridinium toxicity via the STAT3/miR-7/neural precursor cell expressed developmentally down regulated protein 4 (NEDD4) pathway[116]. In epilepsy, EV-delivered circRNA hsa_circ_0000288 regulates cell cycle associated protein 1 (CAPRIN1)/glutamate receptor ionotropic NMDA subunit 3B (NR3B) signaling, reducing hippocampal damage[117]. ADMSC-EVs also inhibit NLRP3-mediated pyroptosis[118]. In schizophrenia models, MSC-EVs protect parvalbumin-positive interneurons and help maintain inhibitory circuit stability[119].

 Critical appraisal and translational gaps

Although SC-EVs reduce markers of apoptosis in preclinical studies, important limitations remain. Most models are based on acute injury paradigms that do not reflect the gradual and region-specific neuronal loss observed in human disease. In addition, many studies rely on short-term or static apoptosis markers, which may not predict long-term neuronal survival or functional integration. Therefore, it remains unclear whether these short-term protective effects translate into sustained functional recovery.

 Regulation of neurogenesis and synaptic plasticity

Impaired neurogenesis and synaptic dysfunction contribute to the progression of multiple neurological disorders. SC-EVs have been reported to promote neural progenitor proliferation, synaptic repair, and plasticity.

Schizophrenia and depression: neurogenesis and synaptic repair

In schizophrenia, MSC-EVs increase the number of doublecortin-positive cells in the hippocampus, suggesting reactivation of neurogenic pathways, potentially through restoration of BDNF signaling. They also upregulate the postsynaptic density protein 95 (PSD-95) and tyrosine hydroxylase, contributing to the stabilization of synaptic structure and dopaminergic neurotransmission[104]. Similar effects have been reported in depressive disorders. BMSC-EVs activate the BDNF/GDNF signaling axis and promote neuronal proliferation in the dentate gyrus (DG)[120]. NSC-EVs, particularly when combined with electroacupuncture, enhance synaptic protein expression, including PSD-95, synaptophysin (SYN), and growth-associated protein 43, thereby facilitating synaptic remodeling[121]. In addition, ADMSC-EVs inhibit Galectin-3-mediated microglial synaptic pruning, which may help preserve synaptic connectivity in the prefrontal cortex[122].

 AD and stroke: restoration of plasticity and network connectivity

In both neurodegenerative and ischemic conditions, SC-EVs contribute to the restoration of neural network integrity. In AD, NSC-EVs and UCMSC-EVs have been shown to partially normalize the expression of genes involved in synaptic plasticity[94,115], which correlates with improved cognitive performance in amyloid precursor protein (APP)/presenilin 1 (PS1) models.

In stroke, SC-EVs support both neurogenesis and structural remodeling in peri-infarct regions. ADMSC-EVs engineered with PD-L1 and hepatocyte growth factor activate the STAT3/forkhead box O3 (FOXO3) pathway and promote neurogenesis[123]. In parallel, NSC-EVs enhance axonal structure and facilitate synaptic reconnection in the ischemic penumbra, contributing to functional recovery[88,107]. These effects are particularly relevant given that post-stroke recovery largely depends on the plasticity of surviving neural tissue.

 Critical appraisal and translational gaps

Although SC-EVs promote neurogenesis and synaptic remodeling in preclinical models, significant translational challenges remain. Species differences in adult neurogenesis limit direct extrapolation to humans. In addition, it remains unclear whether EV-induced neurons and newly formed synapses can achieve stable, long-term functional integration within existing neural circuits in vivo.

 Angiogenesis and BBB integrity

Vascular dysfunction and BBB disruption are key features of both acute ischemic injury and chronic neurodegeneration. Rather than acting solely on neurons, SC-EVs also influence the neurovascular unit by promoting angiogenesis and stabilizing BBB structure.

Stroke: revascularization and barrier defense

In ischemic stroke, therapeutic strategies must balance reperfusion with the risk of secondary injury caused by BBB disruption. SC-EVs contribute to both processes. BMSC-EVs, particularly under hypoxic preconditioning, carry pro-angiogenic microRNAs such as miR-126-3p and miR-140-5p, which enhance endothelial cell migration and tube formation[124]. This response is further supported by increased expression of angiogenic factors, including vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor 2 (VEGFR2), angiopoietin-1 (Ang-1), tyrosine kinase with immunoglobulin and epidermal growth factor homology domains 2 (Tie-2)[125].

In addition, SC-EVs help maintain BBB integrity. BMSC-EVs inhibit Caveolin-1-mediated internalization of tight junction proteins such as zonula occludens-1 (ZO-1) and claudin-5, thereby preserving endothelial barrier structure[126]. They also improve endothelial cell survival under hypoxic conditions through activation of PI3K/AKT and MAPK signaling pathways[122].

 AD: BBB repair and therapeutic delivery

In AD, BBB disruption contributes to disease progression by allowing peripheral inflammatory factors to enter the CNS. SC-EVs can mitigate this process. NSC-EVs have been reported to reduce BBB permeability and partially restore barrier function[127]. UCMSC-EVs suppress the TLR4/NF-κB signaling pathway via miR-125b-5p and provide vascular protection[128].

 Critical appraisal and translational gaps

Although SC-EVs show vascular protective effects in preclinical studies, current models often rely on acute injury paradigms and simplified leakage assays. These approaches do not fully capture the complexity of chronic human vascular dysfunction. In particular, it remains uncertain whether SC-EVs can restore long-term neurovascular coupling and physiological transport across the BBB.

 Regulation of pathological protein aggregation

The accumulation and propagation of misfolded proteins, including Aβ in AD and α-synuclein (α-Syn) in PD, are central to neurodegeneration. SC-EVs influence protein homeostasis through multiple mechanisms, including reducing protein production, enhancing degradation, and promoting clearance.

AD: clearance of Aβ via enzymatic degradation and phagocytosis

In AD, SC-EVs modulate several steps of the amyloid cascade. BMSC-EVs deliver miR-29c-3p, which suppresses β-secretase 1 (BACE1) and reduces the amyloidogenic APP processing[129]. They also promote Aβ clearance by activating the sphingosine kinase (SphK)/sphingosine-1-phosphate (S1P) pathway[114] and increasing the expression of amyloid-degrading enzymes such as neprilysin (NEP) and insulin-degrading enzyme (IDE)[113,130]. In addition, UCMSC-EVs enhance microglial phagocytosis of Aβ deposits, contributing to reduced plaque burden[92,115,131].

 PD: attenuation of α-Syn aggregation and toxicity

In PD, SC-EVs reduce α-Syn accumulation and associated toxicity. Neural-differentiated ADMSC-EVs decrease intracellular α-Syn levels and may limit downstream neuroinflammatory responses[132]. NSC-EVs similarly reduce α-Syn burden in PD models[133]. These effects may alleviate lysosomal stress and help preserve dopaminergic neuron function.

 Critical appraisal and translational gaps

Despite promising findings, current models often rely on artificial overexpression of mutant proteins, which does not fully reflect human disease progression. In addition, many studies focus on end-stage plaque measurements rather than dynamic processes such as oligomer formation and propagation. Therefore, it remains unclear whether SC-EVs can effectively halt long-term protein aggregation and disease progression in vivo.

 Summary of therapeutic mechanisms: the pleiotropic synergy of SC-EVs

SC-EVs exert therapeutic effects through multiple coordinated mechanisms rather than a single target pathway. They deliver a combination of regulatory RNAs and proteins that influence inflammation, apoptosis, oxidative stress, synaptic function, and vascular integrity [Figure 3].

Integrated therapeutic mechanisms of SC-EVs in neurological disorders. This schematic illustrates six major functional pathways: (1) Regulation of Pathological Protein Aggregation to restore proteostasis in AD and PD; (2) Immunomodulation and Anti-Neuroinflammation alongside (3) Neuronal Protection and Anti-Apoptosis, which collectively provide broad cellular defense across acute injuries (stroke), chronic neurodegeneration (AD, PD), and psychiatric/seizure disorders (epilepsy, schizophrenia); (4) Anti-Oxidative Stress responses to restore intracellular redox balance in stroke, PD, and depression; (5) Neuroplasticity enhancement to rebuild synaptic circuitry; and (6) Angiogenesis and BBB Protection to repair the neurovascular unit in stroke and AD. SC-EVs: Stem cell-derived extracellular vesicles; AD: Alzheimer’s disease; PD: Parkinson’s disease; BBB: blood-brain barrier.

Unlike conventional pharmacological agents, EVs represent a cell-free system that retains key functional properties of stem cells while reducing safety concerns associated with cell transplantation. The molecular mediators underlying these effects are summarized in Table 2.

Summary of SC-EV therapeutic mechanisms and targets in neurological disorders

Therapeutic mechanism Cellular origin of SC-EVs Key cargo Target/Pathway Disease type Ref.
Immunomodulation and anti-neuroinflammation BMSC lncRNA ZFAS1 miR-15a-5p Stroke [83]
BMSC Data unavailable NLRP3 Stroke [84]
UCMSC Data unavailable MyD88/TRAF6/NF-κB Depression [105]
ADMSC Data unavailable AMPK-mTOR Depression [106]
UCMSC Data unavailable NRF2 AD [134]
Oxidative stress regulation NSC Data unavailable PINK1/Parkin Stroke [107]
ADMSC miR-23b-3p STAT1/GlyR1 Epilepsy [99]
BMSC miR-146a-5p TRAF6 Epilepsy [135]
UCMSC NRF2, NLRP3 NRF2/NF-κB/NLRP3 Epilepsy [101]
Neuronal protection BMSC lncRNA KLF3-AS1 miR-206/USP22 Stroke [85]
UCMSC TSG-6 STAT3-miR-7-NEDD4 PD [116]
BMSC Data unavailable FTO siRNA; ATM mRNA PD [136]
BMSC Data unavailable miR-26a Depression [108]
BMSC Data unavailable BDNF AD [91]
MSC Data unavailable BDNF Schizophrenia [104]
Neurogenesis promotion BMSC Data unavailable miR-21-5p Stroke [125]
UCMSC Data unavailable BDNF Depression [137]
Synaptogenesis and neuroplasticity regulation ADMSC Data unavailable Galectin-3 Depression [122]
BMSC circRNA hsa_circ_0000288 Caprin1 Epilepsy [117]
Angiogenesis promotion BMSC Data unavailable miR-126-3p; miR-140-5p; let-7c-5p Stroke [124]
Abnormal protein aggregation regulation BMSC Data unavailable miR-29c-3p/BACE1; Wnt/β-catenin AD [129]
UCMSC Data unavailable NEP; miR-211-5p AD [131]
BMSC Data unavailable IDE AD [113]
BMSC Data unavailable SphK/S1P AD [114]

SC-EVs: Stem cell-derived extracellular vesicles; BMSC: bone marrow-derived mesenchymal stem cell; UCMSC: umbilical cord-derived mesenchymal stem cell; ADMSC: adipose-derived mesenchymal stem cell; MSC: mesenchymal stem cell; NSC: neural stem cell; lncRNA: long non-coding RNA; ZFAS1: zinc finger antisense 1; miR: microRNA; NLRP3: NOD-like receptor family pyrin domain containing 3; MyD88: myeloid differentiation primary response 88; TRAF6: TNF receptor-associated factor 6; NF-κB: nuclear factor kappa B; AMPK: AMP-activated protein kinase; mTOR: mechanistic target of rapamycin; AD: Alzheimer’s disease; PINK1: PTEN-induced kinase 1; GlyR1: glycine receptor 1; STAT1: signal transducer and activator of transcription 1; NRF2: nuclear factor erythroid 2-related factor 2; KLF3-AS1: KLF3 antisense RNA 1; USP22: ubiquitin-specific peptidase 22; TSG-6: TNF-stimulated gene 6; STAT3: signal transducer and activator of transcription 3; NEDD4: neural precursor cell expressed developmentally down-regulated protein 4; PD: Parkinson’s disease; FTO: fat mass and obesity-associated protein; siRNA: small interfering RNA; ATM: ataxia telangiectasia mutated; mRNA: messenger RNA; BDNF: brain-derived neurotrophic factor; circRNA: circular RNA; Caprin1: cell cycle-associated protein 1; BACE1: β-site amyloid precursor protein cleaving enzyme 1; NEP: neprilysin; IDE: insulin-degrading enzyme; SphK: sphingosine kinase; S1P: sphingosine-1-phosphate.

 Clinical translation of EV therapy in neurological disorders

SC-EVs have attracted increasing attention in clinical research. Although preclinical studies provide substantial mechanistic evidence, clinical translation remains at an early stage. Most trials are ongoing, and only a limited number have reported completed outcomes[138] [Table 3].

Overview of clinical trials involving SC-EVs for neurological disorders

Disease/Condition NCT Number Sample size Cellular origin of SC-EVs Dosing regimen Phase Endpoints Reported outcomes/Notes
Ischemic stroke NCT06612710 69 Human-induced neural stem cells Patients received intravenous injection of EVs at a dosage of 4 × 109 particles/kg once daily for 7 days Phase 1 Assess the safety; MRI; Scale scores Data unavailable
NCT07232563 9 hUC-MSCs Patients received hUC-MSC-sEV-001 via intranasal instillation at a dosage of 1 × 1011 particles per administration. The treatment was initiated on the day of enrollment and continued daily for 4 days Phase 1 Dose-Limiting Toxicity; Adverse events; Scale scores Data unavailable
Acute ischemic stroke NCT06995625 18 Wharton’s Jelly MSCs EVs were administered once daily for 5 days. There were three cohorts, each with 3 to 6 participants, who received escalating doses: 4.8 × 1010, 9.6 × 1010, and 19.2 × 1010 particles, respectively Phase 1 Assess the safety; Maximum tolerated dose; Assess the efficacy Evidence from non-human primate models underscored the potential for functional neurological restoration
NCT07145294 40 iPSCs EVs (2 mL, 2 × 1010 particles/mL) were administered intranasally twice weekly for 12 weeks, in combination with standard-of-care treatment for cerebrovascular disease Phase 2 Scale scores; Inflammatory indicators; Blood-brain barrier disruption indicators; Neuronal damage indicators Data unavailable
AD NCT04388982 9 Allogeneic adipose MSCs Participants were assigned to three dosage groups: low-dose (5 μg), medium-dose (10 μg), and high-dose (20 μg). All groups received intranasal instillations (1 mL) twice weekly for 12 weeks Phase 2 Assess the safety; Cognitive function; Quality of life evaluation; MRI Neuroimaging; Changes of AD biomarkers The treatment was found to be safe and well-tolerated. Notably, the medium-dose group showed potential cognitive improvements and reduced hippocampal volume loss
PD NCT05152394 20 Allogeneic adult umbilical cord MSCs Participants received two doses of EVs via intranasal instillation on consecutive days. Each dose consisted of 4 mL of solution containing approximately 8 × 1011 exosomes Phase 1 Assess the safety Data unavailable
Refractory focal epilepsy NCT05886205 34 iPSCs Participants were assigned to four cohorts: a low-dose group (2 μg, n = 8), a mid-dose group (6 μg, n = 8), a high-dose group (18 μg, n = 8), and a dose-expansion group (n = 10). All participants received iPSC-Exos (200 μL) via nasal drip twice daily for 12 weeks Early phase 1 Assess the safety; Seizure frequency Data unavailable
Neurodegenerative diseases NCT06607900 120 Human umbilical cord MSCs Intranasal administration Phase 1 Scale scores Data unavailable

EV characterization and QC data are excluded from this table as they are not routinely reported in clinical trial registries prior to formal publication. SC-EVs: Stem cell-derived extracellular vesicles; NCT: National Clinical Trial; hUC-MSCs: human umbilical cord mesenchymal stem cells; MSC: mesenchymal stem cell; sEV: small extracellular vesicle; EV: extracellular vesicle; iPSC: induced pluripotent stem cell; AD: Alzheimer’s disease; PD: Parkinson’s disease; MRI: magnetic resonance imaging.

A completed clinical trial (NCT04388982) evaluated intranasal administration of allogeneic adipose-derived MSC-EVs (ahaMSC-EVs) in patients with mild-to-moderate AD. Participants received treatment twice weekly for 12 weeks across three dose groups. The intranasal route is of particular interest because it enables delivery to the CNS via olfactory and trigeminal pathways, thereby bypassing the BBB. The study demonstrated that repeated administration of ahaMSC-EVs was safe and well tolerated. The medium-dose group showed greater improvement in cognitive function and reduced hippocampal atrophy compared with the other groups[139]. These findings suggest that EV efficacy may not increase linearly with dose, and they highlight the need for optimized dosing strategies and pharmacokinetic characterization in future studies.

 Challenges and bottlenecks in clinical translation

Despite the recognized advantages of SC-EVs, including low immunogenicity and the ability to cross the BBB, their clinical translation remains limited by several challenges. These include technical constraints in production, regulatory complexity, and economic considerations.

 Production standardization and scalability

A major barrier to clinical application is the lack of standardized Good Manufacturing Practice (GMP)-compliant protocols for EV production and characterization. EVs are highly sensitive to the cellular microenvironment; therefore, variations in stem cell source, passage number, and culture conditions (e.g., bioreactor shear stress) can alter EV composition and subpopulation profiles. This variability contributes to inconsistencies in bioactive cargo, including miRNAs and proteins, and compromises reproducibility across batches. In addition, despite the development of MISEV guidelines, standardized and high-throughput methods for particle quantification and surface marker characterization (e.g., CD63, CD81) are still lacking, which further limits comparability between studies[17,140].

 Dosage optimization and efficacy validation

Defining the clinically relevant dosing strategy remains a key pharmacokinetic challenge. Current preclinical studies use heterogeneous dosing regimens, and EVs do not follow conventional small-molecule pharmacokinetics. As a result, dose extrapolation from animal models to humans using standard allometric scaling is unreliable. Moreover, most clinical studies remain exploratory, with limited sample sizes, heterogeneous endpoints, and insufficient long-term follow-up, making it difficult to assess the sustained therapeutic effects[141,142].

 Long-term safety and pharmacokinetics

Long-term biodistribution and safety data for SC-EVs remain limited. Although EVs are thought to preferentially accumulate at sites of injury or inflammation, systemically administered EVs are rapidly cleared by the mononuclear phagocyte system. A substantial proportion accumulates in off-target organs, particularly the liver and spleen. The long-term consequences of this peripheral accumulation, as well as the potential for immune responses following repeated administration, have not yet been fully characterized and require further investigation[143-145].

 Regulatory and economic constraints

The regulatory framework for EV-based therapies is still evolving and varies across regions. Differences in classification criteria between agencies such as the US FDA and the European Medicines Agency (EMA) can lead to divergent approval pathways, particularly for engineered or modified EV products[146,147]. In addition, production costs remain high due to the need for controlled cell culture systems, advanced purification technologies, and comprehensive quality control. Current estimates suggest that EV-based therapies are substantially more expensive than conventional pharmaceuticals[148,149]. However, comprehensive health economic evaluations are still lacking.

These challenges are interrelated and will require coordinated efforts to address. Advances in scalable production technologies, improved standardization, and greater regulatory alignment are needed. Ultimately, well-designed, large-scale clinical trials will be necessary to establish the safety and efficacy of SC-EV-based therapies.

 CONCLUSION

SC-EVs represent a promising approach for the treatment of neurological disorders, owing to their ability to cross the BBB, deliver bioactive cargo, and modulate multiple pathological pathways. Future research should prioritize improving targeting efficiency, optimizing cargo loading, and evaluating combination approaches with existing therapies. EV-associated molecules may also serve as valuable biomarkers for disease monitoring and treatment response[150]. To support clinical translation, standard manufacturing protocols, well-defined dosing strategies, and reliable delivery systems must be established. Addressing these issues will be essential for moving SC-EVs-based therapies from experimental models toward clinical application.

 DECLARATIONS Authors’ contributions

Made substantial contributions to conception and review & editing and design of the study: Ma C, Sun C

Performed original draft, investigation, software and data curation: Fan H, Wang S

Performed original draft and data curation: Li Z, Yu T

 Availability of data and materials

Not applicable.

 AI and AI-assisted tools statement

Not applicable.

 Financial support and sponsorship

This work was supported partly by grants from the National Natural Science Foundation of China (32260194 and 32560199), the Natural Science Foundation of Jiangxi Province (20224BAB206042, 20224BAB206038 and 20252BAC250141).

 Conflicts of interest

All authors declared that there are no conflicts of interest.

 Ethical approval and consent to participate

Not applicable.

 Consent for publication

Not applicable.

 Copyright

© The Author(s) 2026.

 World Health Organization. Global status report on neurology. Available from: https://www.who.int/publications/i/item/9789240116139. [Last accessed on 22 May 2026]. Feigin VL Vos T Nichols E The global burden of neurological disorders: translating evidence into policy Lancet Neurol 2020 19 255 65 10.1016/s1474-4422(19)30411-9 31813850 PMC9945815 Furtado D Björnmalm M Ayton S Bush AI Kempe K Caruso F Overcoming the blood-brain barrier: the role of nanomaterials in treating neurological diseases Adv Mater 2018 30 e1801362 10.1002/adma.201801362 30066406 Ying C Zhang J Zhang H Stem cells in central nervous system diseases: promising therapeutic strategies Exp Neurol 2023 369 114543 10.1016/j.expneurol.2023.114543 37743001 Arbade G Jose JV Gulbake A Kadam S Kashte SB From stem cells to extracellular vesicles: a new horizon in tissue engineering and regenerative medicine Cytotechnology 2024 76 363 401 10.1007/s10616-024-00631-4 38933869 PMC11196501 Zhang X Che X Zhang S Mesenchymal stem cell-derived extracellular vesicles for human diseases Extracell Vesicles Circ Nucl Acids 2024 5 64 82 10.20517/evcna.2023.47 39698413 PMC11648454 Yin T Liu Y He B Cell primitive-based biomimetic nanomaterials for Alzheimer’s disease targeting and therapy Mater Today Bio 2023 22 100789 10.1016/j.mtbio.2023.100789 37706205 PMC10495673 Svendsen SP Svendsen CN Cell therapy for neurological disorders Nat Med 2024 30 2756 70 10.1038/s41591-024-03281-3 39407034 Choudhery MS Arif T Mahmood R Harris DT Stem cell-based acellular therapy: insight into biogenesis, bioengineering and therapeutic applications of exosomes Biomolecules 2024 14 792 10.3390/biom14070792 39062506 PMC11275160 Shi M Chu F Zhu J Stem cells therapy in neurodegenerative and neuroimmune diseases: current status of treatments and future prospects Pharmacol Res 2025 221 107960 10.1016/j.phrs.2025.107960 40976462 Yu S Yu S Liu H Liao N Liu X Enhancing mesenchymal stem cell survival and homing capability to improve cell engraftment efficacy for liver diseases Stem Cell Res Ther 2023 14 235 10.1186/s13287-023-03476-4 37667383 PMC10478247 Su Z Dong H Fang X Zhang W Duan H Frontier progress and translational challenges of pluripotent differentiation of stem cells Front Genet 2025 16 1583391 10.3389/fgene.2025.1583391 40357368 PMC12066753 Stahl PD Raposo G Extracellular vesicles: exosomes and microvesicles, integrators of homeostasis Physiology 2019 34 169 77 10.1152/physiol.00045.2018 30968753 Kalluri R McAndrews KM The role of extracellular vesicles in cancer Cell 2023 186 1610 26 10.1016/j.cell.2023.03.010 37059067 PMC10484374 Wang Y Wang H Tan J Therapeutic effect of mesenchymal stem cells and their derived exosomes in diseases Mol Biomed 2025 6 34 10.1186/s43556-025-00277-4 40465163 PMC12137892 Théry C Witwer KW Aikawa E Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines J Extracell Vesicles 2018 7 1535750 10.1080/20013078.2018.1535750 30637094 PMC6322352 Welsh JA Goberdhan DCI O’Driscoll L ; MISEV Consortium. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches J Extracell Vesicles 2024 13 e12404 10.1002/jev2.12404 38326288 PMC10850029 van Griensven M, Balmayor ER. Extracellular vesicles are key players in mesenchymal stem cells’ dual potential to regenerate and modulate the immune system Adv Drug Deliv Rev 2024 207 115203 10.1016/j.addr.2024.115203 38342242 Pfrieger FW Vitale N Cholesterol and the journey of extracellular vesicles J Lipid Res 2018 59 2255 61 10.1194/jlr.r084210 29678958 PMC6277151 Guevara-Olaya L Chimal-Vega B Castañeda-Sánchez CY LDL promotes disorders in β-cell cholesterol metabolism, implications on insulin cellular communication mediated by EVs Metabolites 2022 12 754 10.3390/metabo12080754 36005626 PMC9415214 Longo A Manganelli V Misasi R Extracellular vesicles in the crosstalk of autophagy and apoptosis: a role for lipid rafts Cells 2025 14 749 10.3390/cells14100749 40422252 PMC12109985 Kalluri R LeBleu VS The biology, function, and biomedical applications of exosomes Science 2020 367 eaau6977 10.1126/science.aau6977 32029601 PMC7717626 Rädler J Gupta D Zickler A Andaloussi SE Exploiting the biogenesis of extracellular vesicles for bioengineering and therapeutic cargo loading Mol Ther 2023 31 1231 50 10.1016/j.ymthe.2023.02.013 36805147 PMC10188647 Gurung S Perocheau D Touramanidou L Baruteau J The exosome journey: from biogenesis to uptake and intracellular signalling Cell Commun Signal 2021 19 47 10.1186/s12964-021-00730-1 33892745 PMC8063428 Padinharayil H Varghese J Wilson C George A Mesenchymal stem cell-derived exosomes: characteristics and applications in disease pathology and management Life Sci 2024 342 122542 10.1016/j.lfs.2024.122542 38428567 Rather HA Almousa S Craft S Deep G Therapeutic efficacy and promise of stem cell-derived extracellular vesicles in Alzheimer’s disease and other aging-related disorders Ageing Res Rev 2023 92 102088 10.1016/j.arr.2023.102088 37827304 PMC10842260 Sawicki S Bugno-Poniewierska M Żurowski J Comparative transcriptome and microRNA profiles of equine mesenchymal stem cells, fibroblasts, and their extracellular vesicles Genes 2025 16 936 10.3390/genes16080936 40869984 PMC12386118 Rezaie J Nejati V Mahmoodi M Ahmadi M Mesenchymal stem cells derived extracellular vesicles: a promising nanomedicine for drug delivery system Biochem Pharmacol 2022 203 115167 10.1016/j.bcp.2022.115167 35820499 Yuan X Sun L Jeske R Engineering extracellular vesicles by three-dimensional dynamic culture of human mesenchymal stem cells J Extracell Vesicles 2022 11 e12235 10.1002/jev2.12235 35716062 PMC9206229 Bertolino GM Maumus M Jorgensen C Noël D Therapeutic potential in rheumatic diseases of extracellular vesicles derived from mesenchymal stromal cells Nat Rev Rheumatol 2023 19 682 94 10.1038/s41584-023-01010-7 37666995 Xiao Y Hoorain I Zhang L Unpacking the anti-fibrotic arsenal: molecular mechanisms and therapeutic translation of MSC-derived exosomes in pulmonary fibrosis Front Immunol 2025 16 1725041 10.3389/fimmu.2025.1725041 41459489 PMC12740883 Yoo D Jung SY Go D Functionalized extracellular vesicles of mesenchymal stem cells for regenerative medicine J Nanobiotechnology 2025 23 219 10.1186/s12951-025-03300-6 40102934 PMC11921732 Li F Zhang J Chen A Combined transplantation of neural stem cells and bone marrow mesenchymal stem cells promotes neuronal cell survival to alleviate brain damage after cardiac arrest via microRNA-133b incorporated in extracellular vesicles Aging 2021 13 262 78 10.18632/aging.103920 33436530 PMC7835040 Tan Q Xia D Ying X miR-29a in exosomes from bone marrow mesenchymal stem cells inhibit fibrosis during endometrial repair of intrauterine adhesion Int J Stem Cells 2020 13 414 23 10.15283/ijsc20049 33250449 PMC7691861 Wei R Zhang L Hu W Shang X He Y Zhang W Zeb2/axin2-enriched BMSC-derived exosomes promote post-stroke functional recovery by enhancing neurogenesis and neural plasticity J Mol Neurosci 2022 72 69 81 10.1007/s12031-021-01887-7 34401997 Ding Z Greenberg ZF Serafim MF Understanding molecular characteristics of extracellular vesicles derived from different types of mesenchymal stem cells for therapeutic translation Extracell Vesicle 2024 3 100034 10.1016/j.vesic.2024.100034 38957857 PMC11218754 Abdal Dayem A Lee SB Kim K Production of mesenchymal stem cells through stem cell reprogramming Int J Mol Sci 2019 20 1922 10.3390/ijms20081922 31003536 PMC6514654 Yamanaka S Pluripotent stem cell-based cell therapy-promise and challenges Cell Stem Cell 2020 27 523 31 10.1016/j.stem.2020.09.014 33007237 Shi Y Yang X Wang S Human umbilical cord mesenchymal stromal cell-derived exosomes protect against MCD-induced NASH in a mouse model Stem Cell Res Ther 2022 13 517 10.1186/s13287-022-03201-7 36371344 PMC9652856 Zhang Z Mi T Jin L Comprehensive proteomic analysis of exosome mimetic vesicles and exosomes derived from human umbilical cord mesenchymal stem cells Stem Cell Res Ther 2022 13 312 10.1186/s13287-022-03008-6 35841000 PMC9284776 Yaghoubi Y Movassaghpour A Zamani M Talebi M Mehdizadeh A Yousefi M Human umbilical cord mesenchymal stem cells derived-exosomes in diseases treatment Life Sci 2019 233 116733 10.1016/j.lfs.2019.116733 31394127 Mazini L Rochette L Amine M Malka G Regenerative capacity of adipose derived stem cells (ADSCs), comparison with mesenchymal stem cells (MSCs) Int J Mol Sci 2019 20 2523 10.3390/ijms20102523 31121953 PMC6566837 Nashwan S Ismail MA Saleh T Comparative analysis of extracellular vesicles from induced and adipose-derived mesenchymal stem cells: implications for regenerative medicine PLoS One 2025 20 e0325065 10.1371/journal.pone.0325065 40465768 PMC12136449 Heo JS Choi Y Kim HO Adipose-derived mesenchymal stem cells promote M2 macrophage phenotype through exosomes Stem Cells Int 2019 2019 7921760 10.1155/2019/7921760 31781246 PMC6875419 Xing X Han S Cheng G Ni Y Li Z Li Z Proteomic analysis of exosomes from adipose-derived mesenchymal stem cells: a novel therapeutic strategy for tissue injury Biomed Res Int 2020 2020 6094562 10.1155/2020/6094562 32190672 PMC7073480 Hong P Yang H Wu Y Li K Tang Z The functions and clinical application potential of exosomes derived from adipose mesenchymal stem cells: a comprehensive review Stem Cell Res Ther 2019 10 242 10.1186/s13287-019-1358-y 31391108 PMC6686455 Tian L Zhang D Wang Z MiR-877, an exosomal miRNA from mechanical stretch induced adipose derived stromal cells, enhances fracture healing in nonunion rats with type 2 diabetes mellitus Stem Cell Res Ther 2025 16 575 10.1186/s13287-025-04692-w 41121215 PMC12542072 Chang LH Wu SC Chen CH Exosomes derived from hypoxia-cultured human adipose stem cells alleviate articular chondrocyte inflammaging and post-traumatic osteoarthritis progression Int J Mol Sci 2023 24 13414 10.3390/ijms241713414 37686220 PMC10487932 Belair C Sim S Kim KY Tanaka Y Park IH Wolin SL The RNA exosome nuclease complex regulates human embryonic stem cell differentiation J Cell Biol 2019 218 2564 82 10.1083/jcb.201811148 31308215 PMC6683745 Kwon MH Song KM Limanjaya A Embryonic stem cell-derived extracellular vesicle-mimetic nanovesicles rescue erectile function by enhancing penile neurovascular regeneration in the streptozotocin-induced diabetic mouse Sci Rep 2019 9 20072 10.1038/s41598-019-54431-4 31882614 PMC6934510 Cruz L Arevalo Romero JA Brandão Prado M Santos TG Hohmuth Lopes M Evidence of extracellular vesicles biogenesis and release in mouse embryonic stem cells Stem Cell Rev Rep 2018 14 262 76 10.1007/s12015-017-9776-7 29032399 Jeske R Bejoy J Marzano M Li Y Human pluripotent stem cell-derived extracellular vesicles: characteristics and applications Tissue Eng Part B Rev 2020 26 129 44 10.1089/ten.teb.2019.0252 31847715 PMC7187972 Liu M Qiu Y Xue Z Small extracellular vesicles derived from embryonic stem cells restore ovarian function of premature ovarian failure through PI3K/AKT signaling pathway Stem Cell Res Ther 2020 11 3 10.1186/s13287-019-1508-2 31900201 PMC6942273 Wang AYL Kao HK Liu YY Loh CYY Engineered extracellular vesicles derived from pluripotent stem cells: a cell-free approach to regenerative medicine Burns Trauma 2025 13 tkaf013 10.1093/burnst/tkaf013 40475972 PMC12140102 Fan C Zhang E Joshi J Yang J Zhang J Zhu W Utilization of human induced pluripotent stem cells for cardiac repair Front Cell Dev Biol 2020 8 36 10.3389/fcell.2020.00036 32117968 PMC7025514 Barreca MM Cancemi P Geraci F Mesenchymal and induced pluripotent stem cells-derived extracellular vesicles: the new frontier for regenerative medicine? Cells 2020 9 1163 10.3390/cells9051163 32397132 PMC7290733 Xu M Chen G Dong Y Stable expression of a truncated TLX variant drives differentiation of induced pluripotent stem cells into self-renewing neural stem cells for production of extracellular vesicles Stem Cell Res Ther 2022 13 436 10.1186/s13287-022-03131-4 36056423 PMC9438273 Wang Y Zhao J Guo Q Neural stem cell-derived exosomes improve neurite outgrowth and cognitive function through transferring miR-132-3p Exp Neurol 2025 388 115224 10.1016/j.expneurol.2025.115224 40113008 Yuan P Ding L Chen H Neural stem cell-derived exosomes regulate neural stem cell differentiation through miR-9-Hes1 axis Front Cell Dev Biol 2021 9 601600 10.3389/fcell.2021.601600 34055767 PMC8155619 Derkus B Isik M Eylem CC Xenogenic neural stem cell-derived extracellular nanovesicles modulate human mesenchymal stem cell fate and reconstruct metabolomic structure Adv Biol 2022 6 e2101317 10.1002/adbi.202101317 35347890 Luo H Ye G Liu Y miR-150-3p enhances neuroprotective effects of neural stem cell exosomes after hypoxic-ischemic brain injury by targeting CASP2 Neurosci Lett 2022 779 136635 10.1016/j.neulet.2022.136635 35436510 Ma K Xu H Zhang J Insulin-like growth factor-1 enhances neuroprotective effects of neural stem cell exosomes after spinal cord injury via an miR-219a-2-3p/YY1 mechanism Aging 2019 11 12278 94 10.18632/aging.102568 31848325 PMC6949049 Doktor F Figueira RL Fortuna V Amniotic fluid stem cell extracellular vesicles promote lung development via TGF-beta modulation in a fetal rat model of oligohydramnios J Control Release 2025 377 427 41 10.1016/j.jconrel.2024.11.043 39577465 Kim T Hong JW Lee LP Efficient methods of isolation and purification of extracellular vesicles Nano Converg 2025 12 45 10.1186/s40580-025-00509-x 40996676 PMC12463815 Li K Guo B Gu J Emerging advances in drug delivery systems (DDSs) for optimizing cancer complications Mater Today Bio 2025 30 101375 10.1016/j.mtbio.2024.101375 39759851 PMC11699619 Ratushnyak MG Shaposhnikova DA Gubani DF Kondratyev KV Characterization of stem cell exosomes isolated by ultracentrifugation, depth filtration, and precipitation with polyethylene glycol Nanotechnologies Russ 2025 20 78 87 10.1134/s2635167625600166 Khan MI Chen K Zhang L Efficient purification of exosomes and subpopulations in fresh bovine milk via fine isolation of free-flow isoelectric focusing in large scale CEJ 2025 508 160850 10.1016/j.cej.2025.160850 Chen S Shiesh SC Lee GB Chen C Two-step magnetic bead-based (2MBB) techniques for immunocapture of extracellular vesicles and quantification of microRNAs for cardiovascular diseases: a pilot study PLoS One 2020 15 e0229610 10.1371/journal.pone.0229610 32101583 PMC7043767 Kverneland AH Østergaard O Emdal KB Svane IM Olsen JV Differential ultracentrifugation enables deep plasma proteomics through enrichment of extracellular vesicles Proteomics 2023 23 e2200039 10.1002/pmic.202200039 36398564 Benmoussa A Michel S Gilbert C Provost P Isolating multiple extracellular vesicles subsets, including exosomes and membrane vesicles, from bovine milk using sodium citrate and differential ultracentrifugation Bio Protoc 2020 10 e3636 10.21769/bioprotoc.3636 33659307 PMC7842771 Nielsen T Kristensen AF Pedersen S Christiansen G Kristensen SR Investigation of procoagulant activity in extracellular vesicles isolated by differential ultracentrifugation J Extracell Vesicles 2018 7 1454777 10.1080/20013078.2018.1454777 29696077 PMC5912197 Langevin SM Kuhnell D Orr-Asman MA Balancing yield, purity and practicality: a modified differential ultracentrifugation protocol for efficient isolation of small extracellular vesicles from human serum RNA Biol 2019 16 5 12 10.1080/15476286.2018.1564465 30604646 PMC6380284 Musante L Tataruch-Weinert D Kerjaschki D Henry M Meleady P Holthofer H Residual urinary extracellular vesicles in ultracentrifugation supernatants after hydrostatic filtration dialysis enrichment J Extracell Vesicles 2017 6 1267896 10.1080/20013078.2016.1267896 28326167 PMC5328348 Soares M Pinto MM Nobre RJ Isolation of extracellular vesicles from human follicular fluid: size-exclusion chromatography versus ultracentrifugation Biomolecules 2023 13 278 10.3390/biom13020278 36830647 PMC9953485 Foers AD Chatfield S Dagley LF Enrichment of extracellular vesicles from human synovial fluid using size exclusion chromatography J Extracell Vesicles 2018 7 1490145 10.1080/20013078.2018.1490145 29963299 PMC6022248 Böing AN van der Pol E Grootemaat AE Coumans FA Sturk A Nieuwland R Single-step isolation of extracellular vesicles by size-exclusion chromatography J Extracell Vesicles 2014 3 23430 10.3402/jev.v3.23430 25279113 PMC4159761 Jung JH Back W Yoon J Dual size-exclusion chromatography for efficient isolation of extracellular vesicles from bone marrow derived human plasma Sci Rep 2021 11 217 10.1038/s41598-020-80514-8 33436891 PMC7804108 Singh M Tiwari PK Kashyap V Kumar S Proteomics of extracellular vesicles: recent updates, challenges and limitations Proteomes 2025 13 12 10.3390/proteomes13010012 40137841 PMC11944546 Yang D Zhang W Zhang H Progress, opportunity, and perspective on exosome isolation - efforts for efficient exosome-based theranostics Theranostics 2020 10 3684 707 10.7150/thno.41580 32206116 PMC7069071 Duong P Chung A Bouchareychas L Raffai RL Cushioned-density gradient ultracentrifugation (C-DGUC) improves the isolation efficiency of extracellular vesicles PLoS One 2019 14 e0215324 10.1371/journal.pone.0215324 30973950 PMC6459479 Parimon T Garrett NE 3rd Chen P Antes TJ Isolation of extracellular vesicles from murine bronchoalveolar lavage fluid using an ultrafiltration centrifugation technique J Vis Exp 2018 141 e58310 10.3791/58310 30474626 PMC8357408 Fortunato D Giannoukakos S Giménez-Capitán A Hackenberg M Molina-Vila MA Zarovni N Selective isolation of extracellular vesicles from minimally processed human plasma as a translational strategy for liquid biopsies Biomark Res 2022 10 57 10.1186/s40364-022-00404-1 35933395 PMC9357340 Yang H Chen J Bone marrow mesenchymal stem cell-derived exosomes carrying long noncoding RNA ZFAS1 alleviate oxidative stress and inflammation in ischemic stroke by inhibiting microRNA-15a-5p Metab Brain Dis 2022 37 2545 57 10.1007/s11011-022-00997-4 35907132 Liu X Zhang M Liu H Bone marrow mesenchymal stem cell-derived exosomes attenuate cerebral ischemia-reperfusion injury-induced neuroinflammation and pyroptosis by modulating microglia M1/M2 phenotypes Exp Neurol 2021 341 113700 10.1016/j.expneurol.2021.113700 33741350 Xie X Cao Y Dai L Zhou D Bone marrow mesenchymal stem cell-derived exosomal lncRNA KLF3-AS1 stabilizes Sirt1 protein to improve cerebral ischemia/reperfusion injury via miR-206/USP22 axis Mol Med 2023 29 3 10.1186/s10020-022-00595-1 36627572 PMC9830826 Zhang Z Ji R Liu Z hUMSC-Exosomes suppress TREM1-p38 MAPK signaling via HMGB1-dependent mechanisms to reprogram microglial function and promote neuroprotection in ischemic stroke J Nanobiotechnology 2025 23 572 10.1186/s12951-025-03652-z 40830888 PMC12363081 Liu Q Ma H Liao J MiR-125a-5p in extracellular vesicles of neural stem cells acts as a crosstalk signal modulating neuroinflammatory microenvironment to alleviate cerebral ischemia-reperfusion injury Theranostics 2025 15 7064 89 10.7150/thno.115993 40585973 PMC12203920 Wang J Zhao M Fu D Human neural stem cell-derived extracellular vesicles protect against ischemic stroke by activating the PI3K/AKT/mTOR pathway Neural Regen Res 2025 20 3245 58 10.4103/nrr.nrr-d-23-01144 39248158 PMC11881723 Wang QS Xiao RJ Peng J Yu ZT Fu JQ Xia Y Bone marrow mesenchymal stem cell-derived exosomal KLF4 alleviated ischemic stroke through inhibiting N6-methyladenosine modification level of Drp1 by targeting lncRNA-ZFAS1 Mol Neurobiol 2023 60 3945 62 10.1007/s12035-023-03301-2 37002530 Cui GH Guo HD Li H RVG-modified exosomes derived from mesenchymal stem cells rescue memory deficits by regulating inflammatory responses in a mouse model of Alzheimer’s disease Immun Ageing 2019 16 10 10.1186/s12979-019-0150-2 31114624 PMC6515654 Liu S Fan M Xu JX Exosomes derived from bone-marrow mesenchymal stem cells alleviate cognitive decline in AD-like mice by improving BDNF-related neuropathology J Neuroinflammation 2022 19 35 10.1186/s12974-022-02393-2 35130907 PMC8822863 Ding M Shen Y Wang P Exosomes isolated from human umbilical cord mesenchymal stem cells alleviate neuroinflammation and reduce amyloid-beta deposition by modulating microglial activation in Alzheimer’s disease Neurochem Res 2018 43 2165 77 10.1007/s11064-018-2641-5 30259257 Losurdo M Pedrazzoli M D’Agostino C Intranasal delivery of mesenchymal stem cell-derived extracellular vesicles exerts immunomodulatory and neuroprotective effects in a 3xTg model of Alzheimer’s disease Stem Cells Transl Med 2020 9 1068 84 10.1002/sctm.19-0327 32496649 PMC7445021 Li B Chen Y Zhou Y Neural stem cell-derived exosomes promote mitochondrial biogenesis and restore abnormal protein distribution in a mouse model of Alzheimer’s disease Neural Regen Res 2024 19 1593 601 10.4103/1673-5374.385839 38051904 PMC10883488 Zhang L Zhan M Sun H Mesenchymal stem-cell-derived exosomes loaded with phosphorus dendrimers and quercetin treat Parkinson’s disease by modulating inflammatory immune microenvironment ACS Appl Mater Interfaces 2025 17 32013 27 10.1021/acsami.5c05809 40388599 Cai Y Zhang MM Wang M Jiang ZH Tan ZG Bone marrow-derived mesenchymal stem cell-derived exosomes containing gli1 alleviate microglial activation and neuronal apoptosis in vitro and in a mouse Parkinson disease model by direct inhibition of Sp1 signaling J Neuropathol Exp Neurol 2022 81 522 34 10.1093/jnen/nlac037 35609560 Zhang ZX Zhou YJ Gu P Exosomes derived from human umbilical cord mesenchymal stem cells alleviate Parkinson’s disease and neuronal damage through inhibition of microglia Neural Regen Res 2023 18 2291 300 10.4103/1673-5374.368300 37056150 PMC10328268 Lee EJ Choi Y Lee HJ Hwang DW Lee DS Human neural stem cell-derived extracellular vesicles protect against Parkinson’s disease pathologies J Nanobiotechnology 2022 20 198 10.1186/s12951-022-01356-2 35468855 PMC9040239 Yang X Yang X Sun A Chen S Wang X Zhao X The miR-23b-3p from adipose-derived stem cell exosomes alleviate inflammation in mice experiencing kainic acid-induced epileptic seizures Neuroreport 2024 35 612 20 10.1097/wnr.0000000000002044 38813900 Derisfard F Jafarinezhad Z Azarpira N Namavar MR Aligholi H Exosomes obtained from human adipose-derived stem cells alleviate epileptogenesis in the pentylenetetrazol model of epilepsy Neuroreport 2025 36 161 8 10.1097/wnr.0000000000002133 39976050 Che J Wang H Dong J Human umbilical cord mesenchymal stem cell-derived exosomes attenuate neuroinflammation and oxidative stress through the NRF2/NF-κB/NLRP3 pathway CNS Neurosci Ther 2024 30 e14454 10.1111/cns.14454 37697971 PMC10916441 Niu Y Wang X Li M Niu B Exosomes from human umbilical cord Mesenchymal stem cells attenuates stress-induced hippocampal dysfunctions Metab Brain Dis 2020 35 1329 40 10.1007/s11011-019-00514-0 32761493 Ma L Xiao C Zhang Z Zhan YA Exosomes secreted from induced pluripotent stem cell ameliorate the lipopolysaccharide induced neuroinflammatory response via lncRNA-0949 Immun Inflamm Dis 2024 12 e1155 10.1002/iid3.1155 38533916 PMC10966914 Zhong XL Huang Y Du Y Unlocking the therapeutic potential of exosomes derived from nasal olfactory mucosal mesenchymal stem cells: restoring synaptic plasticity, neurogenesis, and neuroinflammation in schizophrenia Schizophr Bull 2024 50 600 14 10.1093/schbul/sbad172 38086528 PMC11059802 Li P Zhang F Huang C Exosomes derived from DPA-treated UCMSCs attenuated depression-like behaviors and neuroinflammation in a model of depression induced by chronic stress J Neuroimmune Pharmacol 2024 19 55 10.1007/s11481-024-10154-6 Sun S Rong J Wang C Intranasal administration of exosomes derived from adipose mesenchymal stem cells ameliorates depressive-like behaviors and inhibits inflammation via AMPK/mTOR-mediated autophagy J Affect Disord 2025 382 227 47 10.1016/j.jad.2025.04.059 40250814 Zhao M Wang J Zhu S Human neural stem cell-derived exosomes activate PINK1/Parkin pathway to protect against oxidative stress-induced neuronal injury in ischemic stroke J Transl Med 2025 23 402 10.1186/s12967-025-06283-y 40188077 PMC11971779 Guo H Huang B Wang Y Zhang Y Ma Q Ren Y Bone marrow mesenchymal stem cells-derived exosomes improve injury of hippocampal neurons in rats with depression by upregulating microRNA-26a expression Int Immunopharmacol 2020 82 106285 10.1016/j.intimp.2020.106285 32088640 Abdel-Gawad DRI Khalil F Shehata O Role of bone marrow mesenchymal stem cell-derived exosomes in reducing neurotoxicity and depression-like behaviors induced by doxorubicin in rats Toxicol Res 2024 13 tfae159 10.1093/toxres/tfae159 39371677 PMC11447378 Kuang Y Zheng X Zhang L Adipose-derived mesenchymal stem cells reduce autophagy in stroke mice by extracellular vesicle transfer of miR-25 J Extracell Vesicles 2020 10 e12024 10.1002/jev2.12024 33304476 PMC7710129 Wang Y Niu H Li L Anti-CHAC1 exosomes for nose-to-brain delivery of miR-760-3p in cerebral ischemia/reperfusion injury mice inhibiting neuron ferroptosis J Nanobiotechnology 2023 21 109 10.1186/s12951-023-01862-x 36967397 PMC10041751 Ye YC Chang ZH Wang P Infarct-preconditioning exosomes of umbilical cord mesenchymal stem cells promoted vascular remodeling and neurological recovery after stroke in rats Stem Cell Res Ther 2022 13 378 10.1186/s13287-022-03083-9 35902882 PMC9330700 Ebrahim N Al Saihati HA Alali Z Exploring the molecular mechanisms of MSC-derived exosomes in Alzheimer’s disease: autophagy, insulin and the PI3K/Akt/mTOR signaling pathway Biomed Pharmacother 2024 176 116836 10.1016/j.biopha.2024.116836 38850660 Wang X Yang G Bone marrow mesenchymal stem cells-derived exosomes reduce Aβ deposition and improve cognitive function recovery in mice with Alzheimer’s disease by activating sphingosine kinase/sphingosine-1-phosphate signaling pathway Cell Biol Int 2021 45 775 84 10.1002/cbin.11522 33300254 Chen YA Lu CH Ke CC Mesenchymal stem cell-derived exosomes ameliorate Alzheimer's disease pathology and improve cognitive deficits Biomedicines 2021 9 594 10.3390/biomedicines9060594 34073900 PMC8225157 Huang D Zhang M Tan Z Bone marrow stem cell-exo-derived TSG-6 attenuates 1-methyl-4-phenylpyridinium+-induced neurotoxicity via the STAT3/miR-7/NEDD4/LRRK2 axis J Neuropathol Exp Neurol 2022 81 621 34 10.1093/jnen/nlac049 35773961 Guo L Lv N Ji JL Circular RNA hsa_circ_0000288 protects against epilepsy in mice by binding to and stabilizing caprin1 protein Acta Pharmacol Sin 2025 46 1592 609 10.1038/s41401-025-01486-x 39962265 PMC12099008 Nazari S Pourmand SM Motevaseli E Hassanzadeh G Mesenchymal stem cells (MSCs) and MSC-derived exosomes in animal models of central nervous system diseases: Targeting the NLRP3 inflammasome IUBMB Life 2023 75 794 810 10.1002/iub.2759 37278718 Tsivion-Visbord H Perets N Sofer T Mesenchymal stem cells derived extracellular vesicles improve behavioral and biochemical deficits in a phencyclidine model of schizophrenia Transl Psychiatry 2020 10 305 10.1038/s41398-020-00988-y 32873780 PMC7463024 Liu H Yan XJ Hu JL Pan H Mao X Cheng Y Exosome derived from bone marrow derived mesenchymal stem cells prevents LPS-induced depressive like behaviors Brain Res Bull 2025 231 111527 10.1016/j.brainresbull.2025.111527 40885451 Upadhya R Madhu LN Attaluri S Extracellular vesicles from human iPSC-derived neural stem cells: miRNA and protein signatures, and anti-inflammatory and neurogenic properties J Extracell Vesicles 2020 9 1809064 10.1080/20013078.2020.1809064 32944193 PMC7480597 Fu W Guo Y Wu P hADMSC-Evs attenuates depressive and anxiety - like behaviors in chronic liver disease via suppressing Liver-Brain Galectin3 signaling Brain Behav Immun 2025 130 106082 10.1016/j.bbi.2025.106082 40848998 Lin SL Chang YW Lee W Role of STAT3-FOXO3 signaling in the modulation of neuroplasticity by PD-L1-HGF-decorated mesenchymal stem cell-derived exosomes in a murine stroke model Adv Sci 2024 11 e2404882 10.1002/advs.202404882 39049677 PMC11423231 Gregorius J Wang C Stambouli O Small extracellular vesicles obtained from hypoxic mesenchymal stromal cells have unique characteristics that promote cerebral angiogenesis, brain remodeling and neurological recovery after focal cerebral ischemia in mice Basic Res Cardiol 2021 116 40 10.1007/s00395-021-00881-9 34105014 PMC8187185 Hu H Hu X Li L Exosomes derived from bone marrow mesenchymal stem cells promote angiogenesis in ischemic stroke mice via upregulation of miR-21-5p Biomolecules 2022 12 883 10.3390/biom12070883 35883438 PMC9313463 Li Y Liu B Zhao T Comparative study of extracellular vesicles derived from mesenchymal stem cells and brain endothelial cells attenuating blood-brain barrier permeability via regulating Caveolin-1-dependent ZO-1 and Claudin-5 endocytosis in acute ischemic stroke J Nanobiotechnology 2023 21 70 10.1186/s12951-023-01828-z 36855156 PMC9976550 Liu Y Huber CC Wang H Disrupted blood-brain barrier in 5×FAD mouse model of Alzheimer’s disease can be mimicked and repaired in vitro with neural stem cell-derived exosomes Biochem Biophys Res Commun 2020 525 192 6 10.1016/j.bbrc.2020.02.074 32081424 Qiu L Cai Y Geng Y Mesenchymal stem cell-derived extracellular vesicles attenuate tPA-induced blood-brain barrier disruption in murine ischemic stroke models Acta Biomater 2022 154 424 42 10.1016/j.actbio.2022.10.022 36367475 Sha S Shen X Cao Y Qu L Mesenchymal stem cells-derived extracellular vesicles ameliorate Alzheimer's disease in rat models via the microRNA-29c-3p/BACE1 axis and the Wnt/β-catenin pathway Aging 2021 13 15285 306 10.18632/aging.203088 34086603 PMC8221351 Elia CA Tamborini M Rasile M Intracerebral injection of extracellular vesicles from mesenchymal stem cells exerts reduced Aβ plaque burden in early stages of a preclinical model of Alzheimer’s disease Cells 2019 8 1059 10.3390/cells8091059 31510042 PMC6770482 Chen H Huang Z Lei A Yu X Shen M Wu D miRNA-211-5p inhibition enhances the protective effect of hucMSC-derived exosome in Aβ1-40 -induced SH-SY5Y cells by increasing NEP expression J Biochem Mol Toxicol 2024 38 e23624 10.1002/jbt.23624 38229323 Ramalingam M Jang S Hwang J Cho HH Kim BC Jeong HS Neural-induced human adipose tissue-derived stem cell secretome exerts neuroprotection against rotenone-induced Parkinson's disease in rats Stem Cell Res Ther 2025 16 193 10.1186/s13287-025-04306-5 40254594 PMC12010609 Guo X Xing J Shi X Cao Y An L Effects of neural stem cell-derived exosomes on MPTP-induced Parkinson’s disease in mice Naturwissenschaften 2025 112 53 10.1007/s00114-025-02002-1 40699331 Wang H Liu Y Li J Tail-vein injection of MSC-derived small extracellular vesicles facilitates the restoration of hippocampal neuronal morphology and function in APP / PS1 mice Cell Death Discov 2021 7 230 10.1038/s41420-021-00620-y 34482379 PMC8418600 Huang X Liu X Zeng J Du P Huang X Lin J Bone marrow mesenchymal stem cell-derived exosomal microRNA regulates microglial polarization PeerJ 2023 11 e16359 10.7717/peerj.16359 38025715 PMC10640847 Geng Y Long X Zhang Y FTO-targeted siRNA delivery by MSC-derived exosomes synergistically alleviates dopaminergic neuronal death in Parkinson's disease via m6A-dependent regulation of ATM mRNA J Transl Med 2023 21 652 10.1186/s12967-023-04461-4 37737187 PMC10515429 Costa-Ferro ZSM Cunha RS Rossi EA Extracellular vesicles derived from mesenchymal stem cells alleviate depressive-like behavior in a rat model of chronic stress Life Sci 2025 366-367 123479 10.1016/j.lfs.2025.123479 39983828 Website ClinicalTrials.gov Home Page. Available from https://clinicaltrials.gov/ [accessed 22 May 2026]. Xie X Song Q Dai C Clinical safety and efficacy of allogenic human adipose mesenchymal stromal cells-derived exosomes in patients with mild to moderate Alzheimer’s disease: a phase I/II clinical trial Gen Psychiatr 2023 36 e101143 10.1136/gpsych-2023-101143 37859748 PMC10582850 Thakur A Rai D Global requirements for manufacturing and validation of clinical grade extracellular vesicles J Liq Biopsy 2024 6 100278 10.1016/j.jlb.2024.100278 40027307 PMC11863704 Kim EH Son JP Oh GS Clinical scale MSC-derived extracellular vesicles enhance poststroke neuroplasticity in rodents and non-human primates J Extracell Vesicles 2025 14 e70110 10.1002/jev2.70135 40693599 PMC12281459 Claridge B Lozano J Poh QH Greening DW Development of extracellular vesicle therapeutics: challenges, considerations, and opportunities Front Cell Dev Biol 2021 9 734720 10.3389/fcell.2021.734720 34616741 PMC8488228 Ciullo A Li C Li L Biodistribution of unmodified cardiosphere-derived cell extracellular vesicles using single RNA tracing J Extracell Vesicles 2022 11 e12178 10.1002/jev2.12178 35005847 PMC8743874 Zhang T Zhang L Ma X Song W The tiny giants of regeneration: MSC-derived extracellular vesicles as next-generation therapeutics Front Cell Dev Biol 2025 13 1612589 10.3389/fcell.2025.1612589 40746857 PMC12310703 Wiklander OP Nordin JZ O’Loughlin A Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting J Extracell Vesicles 2015 4 26316 10.3402/jev.v4.26316 25899407 PMC4405624 Silva AKA Morille M Piffoux M Development of extracellular vesicle-based medicinal products: a position paper of the group “Extracellular Vesicle translatiOn to clinicaL perspectiVEs - EVOLVE France” Adv Drug Deliv Rev 2021 179 114001 10.1016/j.addr.2021.114001 34673131 de Almeida Fuzeta M, Gonçalves PP, Fernandes-Platzgummer A, Cabral JMS, Bernardes N, da Silva CL. From promise to reality: bioengineering strategies to enhance the therapeutic potential of extracellular vesicles Bioengineering 2022 9 675 10.3390/bioengineering9110675 36354586 PMC9687169 Reiner AT Witwer KW van Balkom BWM Concise review: developing best-practice models for the therapeutic use of extracellular vesicles Stem Cells Transl Med 2017 6 1730 9 10.1002/sctm.17-0055 28714557 PMC5689784 Tan F Li X Wang Z Li J Shahzad K Zheng J Clinical applications of stem cell-derived exosomes Signal Transduct Target Ther 2024 9 17 10.1038/s41392-023-01704-0 38212307 PMC10784577 Mulet M Sánchez Milán JA Lorca C Oral microbiome-derived proteins in brain extracellular vesicles circulate and tie to specific dysbiotic and neuropathological profiles in age-related dementias Mol Cell Proteomics 2025 24 101464 10.1016/j.mcpro.2025.101464 41237903 PMC12757489